Biogen Inc.

BIIB

$33.71B

Large Cap

NASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaCAMBRIDGE7.6K employees

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 25, 2026

17d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

7 upcoming, 1 past

Phase 2Next

BIIB122 Phase 2 Results Expected

Feb 25, 2026BIIB122650

Primary completion for BIIB122 trial (NCT05348785) in Parkinson Disease

Source

Phase 2

BIIB080 Phase 2 Results Expected

May 14, 2026BIIB080416

Primary completion for BIIB080 trial (NCT05399888) in Mild Cognitive Impairment Due to Alzheimer's Disease

Source

⭐Phase 3

Nusinersen Phase 3 Results Expected

Jul 31, 2026Nusinersen115

Primary completion for Nusinersen trial (NCT04729907) in Muscular Atrophy, Spinal

Source

⭐Phase 3

Litifilimab Phase 3 Results Expected

Sep 30, 2026Litifilimab548

Primary completion for Litifilimab trial (NCT05531565) in Subacute Cutaneous Lupus Erythematosus

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Oct 20, 2026SAGE-217474

Primary completion for Placebo trial (NCT05531565) in Subacute Cutaneous Lupus Erythematosus

Source

⭐Phase 3

Felzartamab Phase 3 Results Expected

Dec 1, 2026Felzartamab120

Primary completion for Felzartamab trial (NCT06685757) in Antibody-mediated Rejection

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Dec 1, 2026SAGE-217120

Primary completion for Placebo trial (NCT06685757) in Antibody-mediated Rejection

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Tofersen

Approved

ALS (SOD1)

OrphanFast TrackBreakthrough

Leqembi

Lecanemab

Approved

Alzheimer Disease

Fast TrackBreakthrough

Salanersen

Phase 3

Muscular Atrophy, Spinal

BIIB019 (Daclizumab High Yield Process)

Phase 3

Relapsing-Remitting Multiple Sclerosis

BG9418 (Interferon beta-1a)

Phase 3

Active Ulcerative Colitis

Glatiramer Acetate

Phase 3

Relapsing-Remitting Multiple Sclerosis

Midazolam

Phase 3

Relapsing-Remitting Multiple Sclerosis

natalizumab

Phase 3

Crohn's Disease

fampridine

Phase 3

Multiple Sclerosis

BG00012

Phase 3

Multiple Sclerosis

BG00012 (dimethyl fumarate)

Phase 3

Healthy

BG00002 (natalizumab)

Phase 3

Multiple Sclerosis, Relapsing-Remitting

Alefacept

Phase 3

Chronic Plaque Psoriasis

Felzartamab

Phase 3

Primary Membranous Nephropathy

Diroximel fumarate

Phase 3

Relapsing Forms of Multiple Sclerosis

Nusinersen

Phase 3

Muscular Atrophy, Spinal

Omaveloxolone

Phase 3

Friedreich Ataxia

SAGE-217 15/20 mg Oral Solution

Phase 3

Postpartum Depression

BIIB017

Phase 3

Relapsing Multiple Sclerosis

BIIB041 (Fampridine-SR)

Phase 3

Multiple Sclerosis

SAGE-217

Phase 3

Bipolar Disorder I

peginterferon beta-1a

Phase 3

Relapsing Multiple Sclerosis

Bardoxolone Methyl

Phase 3

Alport Syndrome

Litifilimab

Phase 3

Lupus Erythematosus, Systemic

ALKS 8700

Phase 3

Relapsing Remitting Multiple Sclerosis

Sertraline

Phase 3

Depressive Disorder, Major

Interferon Beta-1a

Phase 3

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Natalizumab (BG00002)

Phase 3

Multiple Sclerosis

Interferon β-1a

Phase 3

Relapsing-Remitting Multiple Sclerosis

BIIB017 (peginterferon beta-1a)

Phase 3

Multiple Sclerosis, Relapsing-Remitting

tonapofylline

Phase 3

Renal Insufficiency

Avonex

Phase 3

Multiple Sclerosis

dimethyl fumarate

Phase 3

Relapsing-Remitting Multiple Sclerosis

BIIB041 (fampridine)

Phase 3

Multiple Sclerosis, Remittent Progressive

Bardoxolone methyl (amorphous dispersion)

Biogen Inc.

Market Overview

BIIB122 Phase 2 Results Expected

BIIB080 Phase 2 Results Expected

Nusinersen Phase 3 Results Expected

Litifilimab Phase 3 Results Expected

Placebo Phase 3 Results Expected

Felzartamab Phase 3 Results Expected

Placebo Phase 3 Results Expected

AI Predictions & Institutional Flow

FDA Submissions

Drug Pipeline

Regulatory & News